How to appeal an Aetna multiple myeloma (non-car-t) denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna multiple myeloma (non-car-t) denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for multiple myeloma (non-car-t)
Cited policy: Aetna CPB Darzalex / Darzalex Faspro (Daratumumab) for MM
MM diagnosis per IMWG 2014. Approved combinations: NDMM-TE (DVRd / DVTd / DRd), NDMM-TI (DRd / DVMP), RRMM (DRd / DVd / DPd / DKd / DVMP). Faspro SC may be substituted for IV after first cycle or upfront. Hematologist-oncologist Rx. Reauth every 6 mo with response.
How Aetna denies multiple myeloma (non-car-t) — and how to counter it
Where Aetna pushes back: 1) Use Darzalex IV — Faspro more expensive; 2) Faspro restricted to specific combos; 3) Not category-1 in this line.
Counter-arguments that hold up: COLUMBA (Mateos Lancet Haematol 2020;7:e370-e380) — Dara-Faspro SC NON-INFERIOR to IV (ORR + PFS) with infusion reactions 12.7% vs 34.5% IV. 5-min SC vs 6+ hr first IV infusion = substantial chair-time + nursing savings. NCCN MM v3.2024 + FDA label permit Faspro across all daratumumab indications. MAIA / GRIFFIN / CASSIOPEIA / APOLLO included Faspro arms or extensions.
What Aetna typically denies for multiple myeloma (non-car-t)
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For multiple myeloma (non-car-t), expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the multiple myeloma (non-car-t) treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Darzalex IV
- Darzalex Faspro SC
- Sarclisa
- Tecvayli
- Elrexfio
- Talvey
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna multiple myeloma (non-car-t) denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for multiple myeloma (non-car-t)?
For multiple myeloma (non-car-t), Aetna most often denies on: 1) Use Darzalex IV — Faspro more expensive; 2) Faspro restricted to specific combos; 3) Not category-1 in this line. The strongest counters: COLUMBA (Mateos Lancet Haematol 2020;7:e370-e380) — Dara-Faspro SC NON-INFERIOR to IV (ORR + PFS) with infusion reactions 12.7% vs 34.5% IV. 5-min SC vs 6+ hr first IV infusion = substantial chair-time + nursing savings. NCCN MM v3.2024 + FDA label permit Faspro across all daratumumab indications. MAIA / GRIFFIN / CASSIOPEIA / APOLLO included Faspro arms or extensions.
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Multiple myeloma (non-CAR-T) appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com